DNA Testing for Prostate Cancer: Who Should Consider Genetic Testing?

What Does “DNA Screening for Prostate Cancer” Actually Mean?

The phrase “DNA screening” can mean several different things, and this is where patients often become confused.

There are three main categories to understand:

• Germline genetic testing looks for inherited DNA variants present throughout the body.
• Tumor genomic testing examines genetic changes within an existing prostate cancer.
• Blood or urine biomarkers can help estimate the likelihood of clinically significant prostate cancer in selected men, but these are not the same as inherited genetic testing.

What Is Germline Genetic Testing?

Germline testing looks for genetic variants that a person was born with and that may have been inherited from either parent.

The test is usually performed using a sample of:

• blood;
• saliva;
• or sometimes cells collected from inside the cheek.

The laboratory then examines selected genes associated with inherited cancer risk.

According to the National Cancer Institute, prostate cancer has a substantial hereditary component. Some inherited variants can significantly increase risk, while many other common genetic variants each contribute only a small amount to overall risk.

Which Genes Are Associated With Prostate Cancer?

Genes that may be included in hereditary prostate-cancer testing include:

• BRCA2;
• BRCA1;
• ATM;
• CHEK2;
• PALB2;
• HOXB13;
• MLH1;
• MSH2;
• MSH6;
• PMS2;
• and other genes depending on the clinical situation and testing panel.

BRCA2 is particularly important because inherited harmful variants are associated not only with an increased likelihood of prostate cancer but also with a higher risk of more aggressive disease.

Who Should Consider Genetic Testing?

Genetic testing is not automatically necessary for every man.

Doctors usually consider a person’s own cancer history, family history, ancestry and characteristics of any diagnosed prostate cancer before deciding whether germline testing is appropriate.

Testing may be particularly relevant for some men with:

• metastatic prostate cancer;
• high-risk or very-high-risk prostate cancer;
• regional or node-positive prostate cancer;
• a strong family history of prostate cancer;
• relatives who developed prostate cancer at a relatively young age;
• family members who died from prostate cancer;
• a known inherited cancer-associated mutation in the family;
• a family history suggestive of hereditary breast and ovarian cancer;
• a family history of pancreatic, ovarian, male breast or certain other cancers;
• features suggesting Lynch syndrome;
• or tumor testing that finds a genetic alteration that might also be inherited.

The exact criteria vary between guidelines, so genetic counseling or review by a clinician familiar with hereditary cancer can be useful.

Does Family History Matter?

Yes. Family history remains one of the most useful clues that inherited risk may be present.

A doctor may ask whether your father, brothers, sons, grandparents, uncles or other relatives have had:

• prostate cancer, particularly metastatic or aggressive disease;
• breast cancer diagnosed at a young age;
• male breast cancer;
• ovarian cancer;
• pancreatic cancer;
• colorectal or endometrial cancers associated with Lynch syndrome;
• or a previously identified hereditary cancer mutation.

Family history can influence both the decision to perform genetic testing and the age at which prostate-cancer screening discussions begin.

Can Genetic Testing Tell Me Whether I Have Prostate Cancer Right Now?

No. This is the most important correction to the old version of this article.

Germline DNA testing can identify inherited susceptibility, but it does not tell a doctor that a prostate tumor is currently present.

For early detection, clinicians instead consider:

• PSA ;
• age and overall health;
• family history and inherited risk;
• digital rectal examination when appropriate;
• PSA density or other risk calculations;
• multiparametric MRI;
• selected blood or urine biomarkers;
• and prostate biopsy when the estimated risk justifies it.

See my broader guide to prostate tests for an explanation of how these tests fit together.

What Is Tumor Genetic or Genomic Testing?

Tumor testing is different from inherited genetic testing.

If prostate cancer has already been diagnosed, a laboratory may analyze DNA or other molecular features within the tumor itself.

These tumor changes are called somatic alterations. They develop in cancer cells and are not necessarily present in the rest of the body.

Tumor genomic testing can be particularly important in advanced prostate cancer because certain alterations may affect treatment options.

For example, changes involving DNA-repair pathways or mismatch-repair systems may influence whether a patient is eligible for particular targeted therapies or immunotherapy.

What About BRCA1 and BRCA2?

BRCA1 and BRCA2 are often associated in the public mind with breast and ovarian cancer, but they are relevant to men as well.

Inherited harmful BRCA variants can increase prostate-cancer risk, particularly BRCA2.

A man may be more likely to be offered genetic counseling if there is a family pattern involving:

• breast cancer diagnosed at an unusually young age;
• ovarian cancer;
• male breast cancer;
• pancreatic cancer;
• metastatic prostate cancer;
• or a known BRCA variant in the family.

Men known to carry certain inherited variants may also be advised to begin discussions about prostate-cancer screening earlier than men at average risk. NCI notes that some organizations recommend beginning PSA-based screening at around age 40–45 in higher-risk groups, including BRCA2 carriers. :contentReference[oaicite:1]{index=1}

What Is the PCA3 Test?

PCA3 is another area where the original article needs clarification.

PCA3 is not an inherited DNA-risk test. PCA3 refers to prostate cancer gene 3 RNA that can be measured in urine.

The urine sample is traditionally collected after manipulation of the prostate during a digital rectal examination.

NCI notes that PCA3 testing may be considered in selected men with a persistently elevated PSA after a previous negative prostate biopsy when deciding whether another biopsy may be appropriate. :contentReference[oaicite:2]{index=2}

The FDA has also listed the PROGENSA PCA3 assay among nucleic-acid-based tests for prostate cancer. :contentReference[oaicite:3]{index=3}

Are There Other Blood or Urine Tests Besides PSA?

Yes. Modern prostate-cancer evaluation may use selected additional biomarkers when the result would genuinely influence whether a biopsy is performed.

The AUA/SUO guideline states that clinicians may use adjunctive serum or urine markers when additional risk stratification would affect the biopsy decision. These tests are typically considered in men with mildly elevated PSA rather than being used as universal population screening tests. :contentReference[oaicite:4]{index=4}

Examples of current or established biomarker approaches can include tests based on:

• PSA isoforms;
• kallikreins;
• urinary RNA markers;
• and combinations of clinical and molecular measurements.

These tests can sometimes reduce unnecessary biopsies, but they can also miss some clinically important cancers. They should therefore be used selectively, not automatically.

Can a DNA Test Replace PSA Screening?

No.

An inherited genetic test and a PSA test provide completely different information.

What Does a Positive Genetic Test Mean?

A positive result generally means that the laboratory identified a pathogenic or likely pathogenic genetic variant associated with increased cancer risk.

That result may have implications for:

• the patient’s own cancer-screening strategy;
• how an existing prostate cancer is assessed;
• possible treatment choices in certain cancers;
• and blood relatives who may have inherited the same variant.

This is one reason genetic counseling can be particularly valuable.

What Does a Negative Genetic Test Mean?

A negative result does not mean that you cannot develop prostate cancer.

Most prostate cancers are not explained by one identifiable high-risk inherited mutation.

Risk also depends on:

• age;
• family history;
• ancestry;
• many common genetic variants;
• and other biological factors that are not captured by a single clinical genetic test.

For that reason, a negative test should never be interpreted as permission to ignore appropriate prostate-cancer screening or new symptoms.

What Is a Variant of Uncertain Significance?

Genetic testing does not always produce a simple positive or negative answer.

Sometimes a laboratory identifies a variant of uncertain significance, or VUS.

This means that a DNA variation has been found but there is not enough evidence to know whether it meaningfully increases cancer risk.

A VUS generally should not be treated as though it were a confirmed harmful mutation.

NCI specifically notes that variants of uncertain significance can later be reclassified as more evidence becomes available. :contentReference[oaicite:5]{index=5}

Should I Order an At-Home DNA Test?

I would be cautious about using a consumer DNA test as the sole basis for medical decisions about prostate cancer.

Direct-to-consumer tests may examine only a limited selection of variants and may not provide the same coverage as a clinically ordered multigene hereditary cancer panel.

NCI states that at-home genetic tests have important limitations and are not generally recommended as the primary way to determine whether a person has inherited a cancer-predisposing variant. :contentReference[oaicite:6]{index=6}

If family history or your own medical history raises concern, clinical genetic testing accompanied by appropriate counseling is generally more informative.

When Should You Discuss Genetic Counseling?

Consider discussing genetic counseling with your doctor if:

• several relatives have had prostate cancer;
• a close relative developed prostate cancer unusually young;
• there is metastatic prostate cancer in your family;
• your family has breast, ovarian, pancreatic or male breast cancer;
• there is a known BRCA, Lynch syndrome or other hereditary cancer mutation;
• you have high-risk, regional or metastatic prostate cancer;
• your prostate-cancer tumor testing suggests a potentially inherited variant;
• or you are unsure how a commercial DNA result should be interpreted.

Questions to Ask Before Genetic Testing

• Why are you recommending genetic testing for me?
• Are we testing inherited DNA, my tumor, or both?
• Which genes are included in the panel?
• What would a positive result change about my care?
• What would a negative result mean?
• Could the result affect my children, siblings or other relatives?
• What happens if the laboratory finds a variant of uncertain significance?
• Should I meet with a genetic counselor before or after testing?
• Will my prostate-cancer screening change if a high-risk mutation is found?

Related Guides